Abeta mediated diminution of MTT reduction--an artefact of single cell culture?
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) reduction assay is a frequently used and easily reproducible method to measure beta-amyloid (Abeta) toxicity in different types of single cell culture. To our knowledge, the influence of Abeta on MTT reduction has never been tested in more complex tissue. Initially, we reproduced the disturbed MTT reduction in neuron and astroglia primary cell cultures from rats as well as in the BV2 microglia cell line, utilizing four different Abeta species, namely freshly dissolved Abeta (25-35), fibrillar Abeta (1-40), oligomeric Abeta (1-42) and oligomeric Abeta (1-40). In contrast to the findings in single cell cultures, none of these Abeta species altered MTT reduction in rat organotypic hippocampal slice cultures (OHC). Moreover, application of Abeta to acutely isolated hippocampal slices from adult rats and in vivo intracerebroventricular injection of Abeta also did not influence the MTT reduction in the respective tissue. Failure of Abeta penetration into the tissue cannot explain the differences between single cells and the more complex brain tissue. Thus electrophysiological investigations disclosed an impairment of long-term potentiation (LTP) in the CA1 region of hippocampal slices from rat by application of oligomeric Abeta (1-40), but not by freshly dissolved Abeta (25-35) or fibrillar Abeta (1-40). In conclusion, the experiments revealed a glaring discrepancy between single cell cultures and complex brain tissue regarding the effect of different Abeta species on MTT reduction. Particularly, the differential effect of oligomeric versus other Abeta forms on LTP was not reflected in the MTT reduction assay. This may indicate that the Abeta oligomer effect on synaptic function reflected by LTP impairment precedes changes in formazane formation rate or that cells embedded in a more natural environment in the tissue are less susceptible to damage by Abeta, raising cautions against the consideration of single cell MTT reduction activity as a reliable assay in Alzheimer's drug discovery studies.
Rönicke
Raik
R
Project Group Neuropharmacology, Leibniz Institute for Neurobiology, Magdeburg, Germany. roenicke@zenit-magdeburg.de
Klemm
Anja
A
Meinhardt
Jessica
J
Schröder
Ulrich H
UH
Fändrich
Marcus
M
Reymann
Klaus G
KG
D000544:Alzheimer Disease; D016229:Amyloid beta-Peptides / Q000737:chemistry*; D000818:Animals; D001253:Astrocytes / Q000378:metabolism; D001921:Brain / Q000196:embryology; D004594:Electrophysiology; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D017774:Long-Term Potentiation; D008297:Male; D017628:Microglia / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013569:Synapses / Q000378:metabolism; D013778:Tetrazolium Salts / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D016229:Amyloid beta-Peptides; D013778:Tetrazolium Salts; D013844:Thiazoles; C022616:thiazolyl blue
Neurobiol Aging. 2009 Mar;30(3):377-87
17692997
J Lipid Res. 2005 May;46(5):949-68
15716586
J Neurochem. 1995 Dec;65(6):2585-93
7595555
J Neurochem. 1997 May;68(5):1889-95
9109514
Neurosci Res. 1997 Oct;29(2):129-34
9359461
J Neurochem. 1997 Dec;69(6):2285-93
9375659
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53
9600986
Nat Med. 1998 Jul;4(7):827-31
9662375
Neurosci Res. 1998 Aug;31(4):295-305
9809588
Glia. 1999 Feb 15;25(4):390-403
10028921
Neuropharmacology. 2000 Jul 24;39(10):1779-87
10884559
J Neurosci Methods. 2000 Jun 30;99(1-2):1-7
10936637
Eur J Neurosci. 2001 Apr;13(7):1380-6
11298798
Brain Res. 2001 Jul 13;907(1-2):188-94
11430902
Biochem Soc Trans. 2002 Aug;30(4):552-7
12196135
Science. 2003 Apr 18;300(5618):486-9
12702875
Brain Res. 2003 Sep 19;985(1):98-107
12957372
Leuk Lymphoma. 2003 Nov;44(11):1957-62
14738150
Exp Neurol. 2003 Dec;184(2):923-9
14769384
J Cell Mol Med. 2004 Apr-Jun;8(2):241-8
15256072
Eur J Pharmacol. 2004 Oct 11;502(1-2):99-104
15464094
J Biol Chem. 1967 Nov 10;242(21):4987-93
6058941
J Cell Biol. 1981 Nov;91(2 Pt 1):584-8
6796595
Science. 1990 Oct 12;250(4978):279-82
2218531
Am J Pathol. 1993 Jan;142(1):17-24
8424453
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1470-4
8108433
Drug Discov Today. 2005 Jul 15;10(14):993-1000
16023058
Protein Sci. 2005 Aug;14(8):2125-31
15987892
Curr Drug Targets CNS Neurol Disord. 2005 Aug;4(4):435-52
16101559
Brain Res. 2005 Sep 21;1056(2):158-67
16125154
Mol Genet Metab. 2005 Sep-Oct;86(1-2):188-99
15963747
Biochem Soc Trans. 2005 Nov;33(Pt 5):1087-90
16246051
J Neurochem. 2005 Nov;95(3):834-47
16135089
Exp Brain Res. 2006 Jan;168(1-2):11-24
16175362
Exp Mol Med. 2005 Dec 31;37(6):559-66
16391517
J Neurochem. 2006 Feb;96(4):917-23
16412101
Neurobiol Aging. 2006 Apr;27(4):570-5
16481071
FASEB J. 2006 Apr;20(6):714-6
16473887
Amyloid. 2006 Mar;13(1):6-12
16690494
FASEB J. 2006 Jun;20(8):1191-3
16636106
J Biol Chem. 2006 Jul 21;281(29):20315-25
16714296
J Neurosci Methods. 2006 Oct 15;157(1):32-8
16682083
Neuropharmacology. 2007 Jan;52(1):24-40
16919684
J Neurosci. 2007 Mar 14;27(11):2866-75
17360908
Eur J Pharmacol. 2007 Apr 30;561(1-3):85-90
17320856
J Neurochem. 2007 Jun;101(5):1172-84
17286590
J Pharmacol Sci. 2007 May;104(1):46-55
17452809
Exp Brain Res. 2007 Jun;179(4):621-30
17171334
Neuroscience. 2007 Jul 13;147(3):639-51
17560726
Cell Mol Life Sci. 2007 Aug;64(16):2066-78
17530168
Eur J Neurosci. 2007 Oct;26(8):2142-50
17908170
Biochem Soc Trans. 2007 Nov;35(Pt 5):1219-23
17956317
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19232-7
18042730
J Nutr Health Aging. 2008 Jan;12(1):51S-7S
18165846
Biochemistry. 2008 Jan 8;47(1):50-9
18078350
FASEB J. 2008 May;22(5):1552-9
18096814
Prog Neuropsychopharmacol Biol Psychiatry. 1999 Apr;23(3):377-95
10378224
J Biol Chem. 1999 Sep 3;274(36):25945-52
10464339
Nat Neurosci. 2005 Jan;8(1):79-84
15608634
J Neurosci. 2005 Feb 2;25(5):1071-80
15689542
Eur J Pharmacol. 1995 Jan 16;288(2):125-30
7720773